Cancer neoantigens and immunogenicity: mutation position matters
Cancer mutations can elicit protective immunity. Computational methods are critical for selecting these neoantigens for immunotherapy. While significant progress has been made in the field in predicting peptide presentation, our understanding of which mutated peptide is recognized as foreign by T ce...
Main Authors: | Aude-Hélène Capietto, Suchit Jhunjhunwala, Lélia Delamarre |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2020-05-01
|
Series: | Molecular & Cellular Oncology |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/23723556.2020.1740071 |
Similar Items
-
Neoantigen Targeting—Dawn of a New Era in Cancer Immunotherapy?
by: Thomas C. Wirth, et al.
Published: (2017-12-01) -
Targeting neoantigens for cancer immunotherapy
by: Xuan Zhao, et al.
Published: (2021-07-01) -
The landscape of neoantigens and its clinical applications: From immunobiology to cancer vaccines
by: Chiranjib Chakraborty, et al.
Published: (2024-01-01) -
Therapeutic Vaccines Targeting Neoantigens to Induce T-Cell Immunity against Cancers
by: Shih-Cheng Pao, et al.
Published: (2022-04-01) -
Recent advances in neoantigen vaccines for treating non‐small cell lung cancer
by: Shu Su, et al.
Published: (2023-12-01)